Summary
Gilead Sciences, Inc. (GILD) announced on December 5, 2008, through its wholly-owned subsidiary Gilead Sciences Limited (GSL), an amendment to its manufacturing supply agreement with PharmaChem Technologies (Grand Bahama) Ltd. This Addendum extends the agreement for the supply of bulk tenofovir disoproxil fumarate, a key active pharmaceutical ingredient for Gilead's important HIV treatments like Truvada®, Atripla™, and Viread®. The amendment secures GSL's commitment to purchase minimum quantities of this API through 2012, ensuring continued supply chain stability for these critical medications. Additionally, the agreement includes provisions for PharmaChem to purchase necessary raw materials from GSL, fostering a more integrated supply relationship. This extension is strategically important for Gilead as it reinforces the production capabilities for its established and growing HIV franchise.
Key Highlights
- 1Gilead Sciences (GILD) subsidiary GSL amended its supply agreement for tenofovir disoproxil fumarate with PharmaChem Technologies.
- 2The Addendum extends the manufacturing supply agreement through 2012.
- 3GSL is obligated to purchase minimum quantities of bulk tenofovir disoproxil fumarate.
- 4Tenofovir disoproxil fumarate is a key active pharmaceutical ingredient (API) in Gilead's HIV drugs: Truvada®, Atripla™, and Viread®.
- 5The agreement includes a reciprocal arrangement for PharmaChem to purchase certain raw materials from GSL.
- 6This amendment ensures continued supply chain security for critical HIV medications.
- 7The filing date was December 7, 2008, with the event date of December 5, 2008.